Gold prices cool after hitting over 2-week high on Fed independence fears
Investing.com -- iRhythm Technologies, Inc. (NASDAQ:IRTC) reported second quarter earnings that significantly exceeded analyst expectations, driving shares up 13.4% as investors responded positively to the company’s strong performance and raised full-year guidance.
The digital healthcare company posted an adjusted loss of -$0.32 per share for the second quarter, beating analyst estimates of -$0.51 by $0.19. Revenue surged to $186.7 million, a 26.1% increase YoY and well above the consensus estimate of $173.98 million.
iRhythm raised its full-year 2025 revenue guidance to between $720 million and $730 million, substantially higher than the analyst consensus of $695.75 million. The company also expects adjusted EBITDA margin to range from 8.0% to 8.5% of revenues for the year.
"The second quarter of 2025 was another record quarter for iRhythm, with growth of more than 26%, showcasing the strength of our diversified growth strategy," said Quentin Blackford, President and CEO of iRhythm. "Our continued momentum spans three key areas: accelerating growth in our core monitoring business, continued penetration of Zio AT across major health systems, and successful expansion with innovative value-based care partners."
The company’s gross margin improved to 71.2%, up 130 basis points compared to the second quarter of 2024. This improvement was primarily attributed to volume leverage and operational efficiencies, partially offset by increased costs from a higher mix of Zio AT products.
iRhythm reported unrestricted cash, cash equivalents, and marketable securities of $545.5 million as of June 30, 2025.
Recent operational highlights included a strategic partnership with Lucem Health to accelerate early identification of undiagnosed arrhythmias in patients with comorbid conditions, as well as promising results from real-world studies presented at the American Diabetes Association’s Scientific Sessions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.